KemPharm to Present at Multiple Upcoming Investor Conferences May 11, 2022 07:30AM
KemPharm (KMPH) Enters Definitive Collaboration and License Agreement for its ADHD Candidates with Affiliate of Gurnet Point Capital Sep 4, 2019 08:05AM
KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital Sep 4, 2019 08:00AM
KemPharm Reports First Quarter 2019 Results May 14, 2019 04:05PM
KemPharm (KMPH) Prices 8.33M Share Common Offering at $3/Sh Oct 5, 2018 09:25AM


Oct 5, 2018 09:24AM KemPharm Announces Pricing of Public Offering of Common Stock
Oct 4, 2018 04:08PM KemPharm (KMPH) to Offer Common Stock
Oct 4, 2018 04:07PM KemPharm Announces Proposed Public Offering of Common Stock
Sep 4, 2018 04:43PM KemPharm (KMPH) Enters $50M Stock Sale Agreement with RBC
Apr 2, 2018 07:43AM Kempharm (KMPH): Attention Shifting to KP415 Mid-Year Update - RBC
Feb 13, 2018 07:30AM KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Mar 10, 2017 06:56AM KemPharm (KMPH): Story Remains On Track - RBC
Feb 7, 2017 07:30AM KemPharm to Present at Upcoming Investor Conferences
May 6, 2016 06:45AM Kempharm (KMPH) PT Lowered to $14 at RBC Following FDA Panel Vote
Feb 18, 2016 07:30AM KemPharm, Inc. to Present at Upcoming Investor Conferences
Feb 9, 2016 04:01PM KemPharm Announces Closing of $86.25 Million 5.50% Senior Convertible Notes Due 2021
Feb 4, 2016 07:30AM KemPharm Announces Pricing of $75.0 Million 5.50% Senior Convertible Notes Due 2021
Sep 30, 2015 02:19PM RBC Capital Positive on Kempharm (KMPH) Amid KP201 Tamper Study Results
May 11, 2015 07:35AM RBC Capital Starts Kempharm (KMPH) at Outperform
Apr 16, 2015 10:51AM KemPharm (KMPH) IPO Opens Up 7%
Apr 15, 2015 09:11PM KemPharm Announces Pricing of Initial Public Offering